Levosimendan in Europe and China: An Appraisal of Evidence and Context

The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiangqing Kong, Xinqun Hu, Baotong Hua, Francesco Fedele, Dimitrios Farmakis, Piero Pollesello
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/d6ea5947bafb402f8d01baee6e6bf6a7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d6ea5947bafb402f8d01baee6e6bf6a7
record_format	dspace
spelling	oai:doaj.org-article:d6ea5947bafb402f8d01baee6e6bf6a72021-12-04T16:05:18ZLevosimendan in Europe and China: An Appraisal of Evidence and Context10.15420/ecr.2021.411758-37641758-3756https://doaj.org/article/d6ea5947bafb402f8d01baee6e6bf6a72021-11-01T00:00:00Zhttps://www.ecrjournal.com/articleindex/ecr.2021.41https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the profile of levosimendan in clinical trials conducted inside and outside China and grouped the findings under six headings: effects on haemodynamics, effects on natriuretic peptides, effect on symptoms of heart failure, renal effects, effect on survival, and safety profile. Their conclusions are that under each of these headings there are reasonable grounds to expect that the effects and clinical benefits established in trials and with wider clinical use in Europe and elsewhere will accrue also to Chinese patients. Therefore, the authors are confident that global experience with levosimendan provides a reliable guide to its optimal use and likely therapeutic effects in patients in China.Xiangqing KongXinqun HuBaotong HuaFrancesco FedeleDimitrios FarmakisPiero PolleselloRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 16, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Xiangqing Kong Xinqun Hu Baotong Hua Francesco Fedele Dimitrios Farmakis Piero Pollesello Levosimendan in Europe and China: An Appraisal of Evidence and Context
description	The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the profile of levosimendan in clinical trials conducted inside and outside China and grouped the findings under six headings: effects on haemodynamics, effects on natriuretic peptides, effect on symptoms of heart failure, renal effects, effect on survival, and safety profile. Their conclusions are that under each of these headings there are reasonable grounds to expect that the effects and clinical benefits established in trials and with wider clinical use in Europe and elsewhere will accrue also to Chinese patients. Therefore, the authors are confident that global experience with levosimendan provides a reliable guide to its optimal use and likely therapeutic effects in patients in China.
format	article
author	Xiangqing Kong Xinqun Hu Baotong Hua Francesco Fedele Dimitrios Farmakis Piero Pollesello
author_facet	Xiangqing Kong Xinqun Hu Baotong Hua Francesco Fedele Dimitrios Farmakis Piero Pollesello
author_sort	Xiangqing Kong
title	Levosimendan in Europe and China: An Appraisal of Evidence and Context
title_short	Levosimendan in Europe and China: An Appraisal of Evidence and Context
title_full	Levosimendan in Europe and China: An Appraisal of Evidence and Context
title_fullStr	Levosimendan in Europe and China: An Appraisal of Evidence and Context
title_full_unstemmed	Levosimendan in Europe and China: An Appraisal of Evidence and Context
title_sort	levosimendan in europe and china: an appraisal of evidence and context
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/d6ea5947bafb402f8d01baee6e6bf6a7
work_keys_str_mv	AT xiangqingkong levosimendanineuropeandchinaanappraisalofevidenceandcontext AT xinqunhu levosimendanineuropeandchinaanappraisalofevidenceandcontext AT baotonghua levosimendanineuropeandchinaanappraisalofevidenceandcontext AT francescofedele levosimendanineuropeandchinaanappraisalofevidenceandcontext AT dimitriosfarmakis levosimendanineuropeandchinaanappraisalofevidenceandcontext AT pieropollesello levosimendanineuropeandchinaanappraisalofevidenceandcontext
_version_	1718372704268058624

Levosimendan in Europe and China: An Appraisal of Evidence and Context

Ejemplares similares